TY - JOUR
T1 - Association of contrast-induced nephropathy with risk of adverse clinical outcomes in patients with cardiac catheterization
T2 - From the CINC-J study
AU - on behalf of the CINC-J study investigators
AU - Sato, Akira
AU - Aonuma, Kazutaka
AU - Watanabe, Makoto
AU - Hirayama, Atsushi
AU - Tamaki, Nagara
AU - Tsutsui, Hiroyuki
AU - Toyoaki, Murohara
AU - Ogawa, Hisao
AU - Akasaka, Takashi
AU - Yoshimura, Michihiro
AU - Takayama, Tadateru
AU - Sakakibara, Mamoru
AU - Suzuki, Susumu
AU - Ishigami, Kenichi
AU - Onoue, Kenji
AU - Saito, Yoshihiko
N1 - Funding Information:
This study was supported by grants from the Japanese Ministry of Education, Culture, Sports, Science and Technology and the Takeda Science Foundation .
Funding Information:
Atsushi Hirayama: Research Grant, Modest: Shionogi Pharmaceutical Co., Chugai Pharmaceutical Co., Novartis Pharma KK, Goodman Co., Ltd., Zeon Medical Inc., Dainippon Sumitomo Pharma Co., Ltd., Medtronic Japan Co., Ltd., Mochida Pharmaceutical Co., Ltd. Research Grant, Significant: Astellas Pharma Inc., Daiichi-Sankyo Pharmaceutical Co., Sanofi KK, Nippon Boehringer Ingelheim Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kowa Co., Ltd., Kissei Pharmaceutical Co., Ltd., MSD, Eisai Co., Ltd., Pfizer Japan, Otsuka Pharmaceutical Co., Tanabe Mitsubishi Pharmaceutical Co., AstraZeneca Co., Nihon Medi-Physics Co., Ltd. Honoraria, Significant: Astellas Pharma Inc., Daiichi-Sankyo Pharmaceutical Co., Sanofi KK, Kyowa Hakko Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kowa Co., Ltd.
Funding Information:
Nagara Tamaki: Research Grant, Significant: Hitachi, Ltd., Nihon Medi-Physics Co., Ltd., Smoking Research Foundation, Shionogi & Co., Ltd. Scholarship funds or donations: Nihon Medi-Physics Co., Ltd., Shionogi & Co., Ltd. Endowed departments by commercial entities: Shionogi & Co., Ltd.
Funding Information:
Yoshihiko Saito: Research Grant, Significant: MSD Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Ltd., Honoraria, Modest: MSD Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Company Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc. Endowed departments by commercial entities, MSD Co., Ltd.
Publisher Copyright:
© 2016 Elsevier Ireland Ltd
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2017/1/15
Y1 - 2017/1/15
N2 - Background The association between the incidence of contrast-induced nephropathy (CIN) and subsequent clinical outcomes is unclear in Japan. We evaluated the association between CIN and cardiovascular and renal events after cardiac catheterization. Methods The CINC-J multicenter prospective cohort study examined 853 patients undergoing cardiac catheterization from 27 hospitals. CIN was defined as increase in serum creatinine (SCr) ≥ 0.5 mg/dL or ≥ 25% from baseline between 48 and 72 h after exposure to contrast. Major adverse cardiovascular and cerebrovascular events (MACCE) included all-cause deaths, non-fatal myocardial infarction, acute decompensated heart failure (ADHF), and stroke. Renal events included newly-required hemodialysis and increase of SCr ≥ 2 × from baseline. Results During follow-up periods (477 ± 214 days), CIN, MACCE, and renal events occurred in 44 (5.2%), 71 (8.3%), and 26 (3.0%) patients, respectively. Kaplan–Meier analysis showed that CIN yielded increasing risk for MACCE, ADHF, newly-required hemodialysis, and renal events. In multivariable Cox proportional hazards analysis, age (HR: 1.03; 95% CI, 1.00–1.07; P = 0.0425), anemia (HR: 1.94; 95% CI, 1.08–3.61; P = 0.0264), and diabetes mellitus (HR: 1.86; 95% CI, 1.10–3.21; P = 0.0119) were independent predictors of MACCE, whereas CIN (HR: 7.78; 95% CI, 3.23–17.9; P = 0.0005) and SCr (HR: 2.09; 95% CI, 1.56–2.73; P = 0.0006) were independent predictors of renal events. Compared to subjects without both anemia and CIN as the reference, those with both were high risk for MACCE (HR: 3.97; 95% CI, 1.25–10.6; P = 0.0218). Conclusion CIN was a significant predictor of subsequent renal events after cardiac catheterization. CIN and anemia were associated with increased risk for worse long-term clinical outcome, especially when both were present.
AB - Background The association between the incidence of contrast-induced nephropathy (CIN) and subsequent clinical outcomes is unclear in Japan. We evaluated the association between CIN and cardiovascular and renal events after cardiac catheterization. Methods The CINC-J multicenter prospective cohort study examined 853 patients undergoing cardiac catheterization from 27 hospitals. CIN was defined as increase in serum creatinine (SCr) ≥ 0.5 mg/dL or ≥ 25% from baseline between 48 and 72 h after exposure to contrast. Major adverse cardiovascular and cerebrovascular events (MACCE) included all-cause deaths, non-fatal myocardial infarction, acute decompensated heart failure (ADHF), and stroke. Renal events included newly-required hemodialysis and increase of SCr ≥ 2 × from baseline. Results During follow-up periods (477 ± 214 days), CIN, MACCE, and renal events occurred in 44 (5.2%), 71 (8.3%), and 26 (3.0%) patients, respectively. Kaplan–Meier analysis showed that CIN yielded increasing risk for MACCE, ADHF, newly-required hemodialysis, and renal events. In multivariable Cox proportional hazards analysis, age (HR: 1.03; 95% CI, 1.00–1.07; P = 0.0425), anemia (HR: 1.94; 95% CI, 1.08–3.61; P = 0.0264), and diabetes mellitus (HR: 1.86; 95% CI, 1.10–3.21; P = 0.0119) were independent predictors of MACCE, whereas CIN (HR: 7.78; 95% CI, 3.23–17.9; P = 0.0005) and SCr (HR: 2.09; 95% CI, 1.56–2.73; P = 0.0006) were independent predictors of renal events. Compared to subjects without both anemia and CIN as the reference, those with both were high risk for MACCE (HR: 3.97; 95% CI, 1.25–10.6; P = 0.0218). Conclusion CIN was a significant predictor of subsequent renal events after cardiac catheterization. CIN and anemia were associated with increased risk for worse long-term clinical outcome, especially when both were present.
UR - http://www.scopus.com/inward/record.url?scp=85004024071&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85004024071&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2016.11.019
DO - 10.1016/j.ijcard.2016.11.019
M3 - Article
C2 - 27838134
AN - SCOPUS:85004024071
SN - 0167-5273
VL - 227
SP - 424
EP - 429
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -